FDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study

By: via Benzinga
Inovio Pharmaceuticals Inc (NASDAQ: INO) announced Thursday morning it has commenced a Phase III clinical program (called REVEAL) to ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.